Loss of TGFβ signaling promotes colon cancer progression and tumor-associated inflammation

Oncotarget

Volumn 8, Issue 3, 2017, Pages 3826-3839

  Principe, Daniel R ^a   DeCant, Brian ^b   Staudacher, Jonas ^b   Vitello, Dominic ^c   Mangan, Riley J ^b   Wayne, Elizabeth A ^b,c   Mascariñas, Emman ^b   Diaz, Andrew M ^b   Bauer, Jessica ^b   McKinney, Ronald D ^b   Khazaie, Khashayarsha ^d   Pasche, Boris ^e   Dawson, David W ^f   Munshi, Hidayatullah G ^c   Grippo, Paul J ^b   Jung, Barbara ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d MAYO GRADUATE SCHOOL   (United States)

^e WAKE FOREST BAPTIST HEALTH   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Colon cancer; Inflammation; TGF beta

Indexed keywords

CD11B ANTIGEN; CD3 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 8; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA2; SMAD4 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; ADENOMATOUS POLYPOSIS COLI PROTEIN, MOUSE; APC PROTEIN; CYTOKINE; SMAD4 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ADENOMATOUS POLYP; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER INFILTRATION; CARCINOGENESIS; CELL POPULATION; COLON CANCER; CONTROLLED STUDY; CORRELATIONAL STUDY; EPITHELIUM CELL; GRANULOCYTE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; INFLAMMATION; MESENTERY LYMPH NODE; MOUSE; MOUSE MODEL; MUTANT; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPLEEN; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; COLON TUMOR; DISEASE EXACERBATION; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; COLONIC NEOPLASMS; CYTOKINES; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASMS, EXPERIMENTAL; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 85012001400     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9830     Document Type: Article

References (37)

1. Bailey CE, Hu CY, You YN, Bednarski BK, Rodriguez-Bigas MA, Skibber JM, Cantor SB and Chang GJ. Increasing Disparities in the Age-Related Incidences of Colon and Rectal Cancers in the United States, 1975-2010. JAMA surgery. 2014:1-6.
2. Phipps AI, Limburg PJ, Baron JA, Burnett-Hartman AN, Weisenberger DJ, Laird PW, Sinicrope FA, Rosty C, Buchanan DD, Potter JD and Newcomb PA. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015; 148(1):77-87 e72.
3. Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, Pasche B, Lee C and Grippo PJ. TGFbeta: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst. 2014; 106(2):djt369.
4. Wang J, Sun L, Myeroff L, Wang X, Gentry LE, Yang J, Liang J, Zborowska E, Markowitz S, Willson JK and Brattain MG. Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. The Journal of biological chemistry. 1995; 270(37):22044-22049.
5. Takaku K, Oshima M, Miyoshi H, Matsui M, Seldin MF and Taketo MM. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell. 1998; 92(5):645-656.
6. Bauer J, Sporn JC, Cabral J, Gomez J and Jung B. Effects of activin and TGFbeta on p21 in colon cancer. PLoS One. 2012; 7(6):e39381.
7. Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Cespedes MV, Sevillano M, Nadal C, Jung P, Zhang XH, Byrom D, Riera A, Rossell D, et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer cell. 2012; 22(5):571-584.
8. Langenskiold M, Holmdahl L, Falk P, Angenete E and Ivarsson ML. Increased TGF-beta 1 protein expression in patients with advanced colorectal cancer. J Surg Oncol. 2008; 97(5):409-415.
9. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, Zhang M, Papadopoulos N, Kinzler KW, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer discovery. 2015; 5(1):43-51.
10. Zhang Y, Sime W, Juhas M and Sjolander A. Crosstalk between colon cancer cells and macrophages via inflammatory mediators and CD47 promotes tumour cell migration. European journal of cancer. 2013; 49(15):3320-3334.
11. Erreni M, Mantovani A and Allavena P. Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer microenvironment: official journal of the International Cancer Microenvironment Society. 2011; 4(2):141-154.
12. Fu S, Zhang N, Yopp AC, Chen D, Mao M, Chen D, Zhang H, Ding Y and Bromberg JS. TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25-precursors. Am J Transplant. 2004; 4(10):1614-1627.
13. Miossec P and Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nature reviews Drug discovery. 2012; 11(10):763-776.
14. Gong D, Shi W, Yi SJ, Chen H, Groffen J and Heisterkamp N. TGFbeta signaling plays a critical role in promoting alternative macrophage activation. BMC immunology. 2012; 13:31.
15. Danielson KG, Ohi S and Huang PC. Immunochemical detection of metallothionein in specific epithelial cells of rat organs. Proc Natl Acad Sci U S A. 1982; 79(7):2301-2304.
16. Fearnhead NS, Britton MP and Bodmer WF. The ABC of APC. Human molecular genetics. 2001; 10(7):721-733.
17. Principe DR, DeCant B, Mascarinas E, Wayne E, Diaz A, Akagi N, Hwang RF, Pasche B, Dawson DW, Fang D, Bentrem DJ, Munshi HG, Jung B, et al.TGFbeta signaling in the pancreatic tumor microenvironment promotes fibrosis and immune evasion to facilitate tumorigenesis. Cancer Res. 2016.
18. Hoosein NM, McKnight MK, Levine AE, Mulder KM, Childress KE, Brattain DE and Brattain MG. Differential sensitivity of subclasses of human colon carcinoma cell lines to the growth inhibitory effects of transforming growth factor-beta 1. Experimental cell research. 1989; 181(2):442-453.
19. Padua D and Massague J. Roles of TGFbeta in metastasis. Cell Res. 2009; 19(1):89-102.
20. Wu SP, Theodorescu D, Kerbel RS, Willson JK, Mulder KM, Humphrey LE and Brattain MG. TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. The Journal of cell biology. 1992; 116(1):187-196.
21. Valle L, Serena-Acedo T, Liyanarachchi S, Hampel H, Comeras I, Li Z, Zeng Q, Zhang HT, Pennison MJ, Sadim M, Pasche B, Tanner SM and de la Chapelle A. Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer. Science. 2008; 321(5894):1361-1365.
22. Mesker WE, Liefers GJ, Junggeburt JM, van Pelt GW, Alberici P, Kuppen PJ, Miranda NF, van Leeuwen KA, Morreau H, Szuhai K, Tollenaar RA and Tanke HJ. Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Cellular oncology: the official journal of the International Society for Cellular Oncology. 2009; 31(3):169-178.
23. Ahn BK, Jang SH, Paik SS and Lee KH. Smad4 may help to identify a subset of colorectal cancer patients with early recurrence after curative therapy. Hepato-gastroenterology. 2011; 58(112):1933-1936.
24. Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Jarvinen H, Mecklin JP, Hemminki A, Schwartz S, Jr., Aaltonen LA and Arango D. SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res. 2005; 11(7):2606-2611.
25. Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S and Cohen A. High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev. 1995; 4(5):549-554.
26. Popat S, Hubner R and Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23(3):609-618.
27. Gulubova M, Ananiev J, Yovchev Y, Julianov A, Karashmalakov A and Vlaykova T. The density of macrophages in colorectal cancer is inversely correlated to TGF-beta1 expression and patients' survival. Journal of molecular histology. 2013; 44(6):679-692.
28. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A and Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007; 13(5):1472-1479.
29. Lewis CE and Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer research. 2006; 66(2):605-612.
30. Mei Z, Liu Y, Liu C, Cui A, Liang Z, Wang G, Peng H, Cui L and Li C. Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. British journal of cancer. 2014; 110(6):1595-1605.
31. Itzkowitz SH and Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. American journal of physiology Gastrointestinal and liver physiology. 2004; 287(1):G7-17.
32. Scheinin T, Butler DM, Salway F, Scallon B and Feldmann M. Validation of the interleukin-10 knockout mouse model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis. Clinical and experimental immunology. 2003; 133(1):38-43.
33. Kulkarni AB and Karlsson S. Transforming growth factorbeta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. Am J Pathol. 1993; 143(1):3-9.
34. Zhang N and Bevan MJ. TGF-beta signaling to T cells inhibits autoimmunity during lymphopenia-driven proliferation. Nat Immunol. 2012; 13(7):667-673.
35. De Bosscher K, Hill CS and Nicolas FJ. Molecular and functional consequences of Smad4 C-terminal missense mutations in colorectal tumour cells. The Biochemical journal. 2004; 379(Pt 1):209-216.
36. Oshima H, Nakayama M, Han TS, Naoi K, Ju X, Maeda Y, Robine S, Tsuchiya K, Sato T, Sato H, Taketo MM and Oshima M. Suppressing TGFbeta signaling in regenerating epithelia in an inflammatory microenvironment is sufficient to cause invasive intestinal cancer. Cancer research. 2015; 75(4):766-776.
37. Strober W and Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011; 140(6):1756-1767.